相似文献
1
Genetic analysis of primaquine tolerance in a patient with relapsing vivax malaria.
Emerg Infect Dis. 2013 May;19(5):802-5. doi: 10.3201/eid1905.121852.
2
Multiple relapses of Plasmodium vivax malaria acquired from West Africa and association with poor metabolizer CYP2D6 variant: a case report.
BMC Infect Dis. 2019 Aug 9;19(1):704. doi: 10.1186/s12879-019-4357-9.
3
In vivo therapeutic efficacy of chloroquine alone or in combination with primaquine against vivax malaria in Kolkata, West Bengal, India, and polymorphism in pvmdr1 and pvcrt-o genes.
Antimicrob Agents Chemother. 2013 Mar;57(3):1246-51. doi: 10.1128/AAC.02050-12. Epub 2012 Dec 21.
4
Management of relapsing Plasmodium vivax malaria.
Expert Rev Anti Infect Ther. 2016 Oct;14(10):885-900. doi: 10.1080/14787210.2016.1220304. Epub 2016 Aug 31.
5
Imported tertian malaria resistant to primaquine.
Korean J Intern Med. 1999 Jul;14(2):86-9. doi: 10.3904/kjim.1999.14.2.86.
6
Studies on a primaquine-tolerant strain of Plasmodium vivax from Brazil in Aotus and Saimiri monkeys.
J Parasitol. 1997 Aug;83(4):739-45.
7
Association of Impaired Cytochrome P450 2D6 Activity Genotype and Phenotype With Therapeutic Efficacy of Primaquine Treatment for Latent Plasmodium vivax Malaria.
JAMA Netw Open. 2018 Aug 3;1(4):e181449. doi: 10.1001/jamanetworkopen.2018.1449.
8
Is primaquine useful and safe as true exo-erythrocytic merontocidal, hypnozoitocidal and gametocidal antimalarial drug?
Salud Publica Mex. 1999 Sep-Oct;41(5):410-9. doi: 10.1590/s0036-36341999000500010.
9
Genotyping of Plasmodium vivax reveals both short and long latency relapse patterns in Kolkata.
PLoS One. 2012;7(7):e39645. doi: 10.1371/journal.pone.0039645. Epub 2012 Jul 13.
10
Diagnostic and therapeutic pitfalls associated with primaquine-tolerant Plasmodium vivax.
J Clin Microbiol. 2005 Feb;43(2):978-81. doi: 10.1128/JCM.43.2.978-981.2005.
引用本文的文献
1
Quest for malaria management using natural remedies.
Front Pharmacol. 2024 Jun 26;15:1359890. doi: 10.3389/fphar.2024.1359890. eCollection 2024.
2
Novel highly-multiplexed AmpliSeq targeted assay for genetic surveillance use cases at multiple geographical scales.
Front Cell Infect Microbiol. 2022 Aug 11;12:953187. doi: 10.3389/fcimb.2022.953187. eCollection 2022.
3
Whole Genome Sequencing Contributions and Challenges in Disease Reduction Focused on Malaria.
Biology (Basel). 2022 Apr 13;11(4):587. doi: 10.3390/biology11040587.
4
A molecular barcode to inform the geographical origin and transmission dynamics of Plasmodium vivax malaria.
PLoS Genet. 2020 Feb 13;16(2):e1008576. doi: 10.1371/journal.pgen.1008576. eCollection 2020 Feb.
5
The genomic architecture of antimalarial drug resistance.
Brief Funct Genomics. 2019 Sep 24;18(5):314-328. doi: 10.1093/bfgp/elz008.
6
Cytochrome P450 2D6 profiles and their relationship with outcomes of primaquine anti-relapse therapy in Australian Defence Force personnel deployed to Papua New Guinea and East Timor.
Malar J. 2019 Apr 18;18(1):140. doi: 10.1186/s12936-019-2774-2.
7
Effects of MAO-A and CYP450 on primaquine metabolism in healthy volunteers.
Parasitol Res. 2019 Mar;118(3):1011-1018. doi: 10.1007/s00436-019-06210-3. Epub 2019 Jan 31.
8
A novel immortalized hepatocyte-like cell line (imHC) supports in vitro liver stage development of the human malarial parasite Plasmodium vivax.
Malar J. 2018 Jan 25;17(1):50. doi: 10.1186/s12936-018-2198-4.
9
Molecular and immunological analyses of confirmed Plasmodium vivax relapse episodes.
Malar J. 2017 May 30;16(1):228. doi: 10.1186/s12936-017-1877-x.
10
A chimeric protein-based malaria vaccine candidate induces robust T cell responses against Plasmodium vivax MSP1.
Sci Rep. 2016 Oct 6;6:34527. doi: 10.1038/srep34527.
本文引用的文献
1
The malaria parasite Plasmodium vivax exhibits greater genetic diversity than Plasmodium falciparum.
Nat Genet. 2012 Sep;44(9):1046-50. doi: 10.1038/ng.2373. Epub 2012 Aug 5.
2
CYP450 phenotyping and accurate mass identification of metabolites of the 8-aminoquinoline, anti-malarial drug primaquine.
Malar J. 2012 Aug 2;11:259. doi: 10.1186/1475-2875-11-259.
3
Relapse of imported Plasmodium vivax malaria is related to primaquine dose: a retrospective study.
Malar J. 2012 Jun 22;11:214. doi: 10.1186/1475-2875-11-214.
4
Relapse of imported vivax malaria despite standard-dose primaquine therapy: an investigation with molecular genotyping analyses.
Clin Microbiol Infect. 2012 Jul;18(7):E232-4. doi: 10.1111/j.1469-0691.2012.03820.x. Epub 2012 Mar 27.
5
Human genetic variation is associated with Plasmodium falciparum drug resistance.
J Infect Dis. 2011 Dec 1;204(11):1772-8. doi: 10.1093/infdis/jir629. Epub 2011 Oct 12.
6
The international limits and population at risk of Plasmodium vivax transmission in 2009.
PLoS Negl Trop Dis. 2010 Aug 3;4(8):e774. doi: 10.1371/journal.pntd.0000774.
7
Resistance to therapies for infection by Plasmodium vivax.
Clin Microbiol Rev. 2009 Jul;22(3):508-34. doi: 10.1128/CMR.00008-09.
8
New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance.
Curr Opin Infect Dis. 2009 Oct;22(5):430-5. doi: 10.1097/QCO.0b013e32832f14c1.
9
Disruption of a Plasmodium falciparum multidrug resistance-associated protein (PfMRP) alters its fitness and transport of antimalarial drugs and glutathione.
J Biol Chem. 2009 Mar 20;284(12):7687-96. doi: 10.1074/jbc.M806944200. Epub 2008 Dec 31.
10
Pharmacogenetics of cytochromes P450 in tropical medicine.
Curr Drug Targets. 2006 Dec;7(12):1709-19. doi: 10.2174/138945006779025347.
Zotero 插件